Previous 10 | Next 10 |
Enlivex Therapeutics' (ENLV) underwriter has agreed to increase the size of previous offering and purchase ~2.3M ordinary shares at $20.00/share.Expected gross proceeds are ~$46M. Underwriter's over-allotment is an additional ~344.4K shares. Net proceeds will be used for clinical, regulatory,...
Nes Ziona, Israel, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced that due to demand, the underwrit...
Enlivex Therapeutics (ENLV) enters agreement with underwriter to purchase 500,000 ordinary shares at a price of $20.00 per share.Offering is expected to occur on or about February 12, 2021. Net proceeds from this offering for (i) clinical, regulatory, manufacturing and research and ...
Nes Ziona, Israel, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced that it has entered into an under...
KalVista Pharmaceuticals (KALV) +207% on reporting positive results for KVD900.Comstock Holding Companies (CHCI) +163%.Applied UV (AUVI) +88% after acquiring Airocide Technology Platform.Heat Biologics (HTBX) +47% on announcing positive interim survival data from ongoing HS-110...
Enlivex Therapeutics (ENLV) soars 20% premarket following positive top-line results from Phase II clinical trial evaluating Allocetra in severe and critical COVID-19 patients. Of the 16 sixteen patients enrolled, 9/16 (56%) were in severe condition and 7/16 (44%) were in c...
Phase II (16 patients treated, 9/16 (56%) with severe illness, 7/16 (44%) with critical illness, follow-up period of 28 days post-Allocetra TM treatment) 0/16 (0%) mortality on day-28 14/16 (87.5%) patients recovered and were discharged from the hospital by day-2...
Nes Ziona, Israel, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that Company management will present at the H.C. Wainwright BioConnect 2021 Virtua...
– Comparison of 10 Allocetra TM -treated patients with 37 matched controls showed significant positive responses in state of organ failure, duration of ICU stay and mortality in a highly fragile and extremely difficult to treat population with severe sepsis – Nes Ziona...
Takung Art (TKAT) +81%.Evolus (EOLS) +43% after company updates on U.S. ITC case related to Jeuveau sales and marketing.Skillful Craftsman Education Technology (EDTK) +17%.Marathon Patent Group (MARA) +23%.Rite Aid Corporation (RAD) +21% on Q3 results.Vivos Therapeuti...
News, Short Squeeze, Breakout and More Instantly...
Enlivex Therapeutics Ltd. Company Name:
ENLV Stock Symbol:
NYSE Market:
Enlivex Therapeutics Ltd. Website:
• First study of Allocetra TM in psoriatic arthritis, a chronic inflammatory condition that causes joint pain, swelling and stiffness, affects as many as 30% of people with psoriasis 1 , and has limited treatment options Nes-Ziona, Israel, July 23, 2024 (GLOB...
ORLANDO, FL / ACCESSWIRE / July 19, 2024 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 20, at 7 p.m. Eastern T...
First patient dosed with Allocetra TM in thumb osteoarthritis, a degenerative, debilitating and progressive disease that affects millions of people Thumb osteoarthritis currently has no FDA-approved therapy and no effective long-term treatments Ness-Ziona, Israel, June 24, 2024 (GLO...